[Federal Register Volume 64, Number 158 (Tuesday, August 17, 1999)]
[Notices]
[Page 44690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-21205]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Notice of Prospective Grant of Exclusive Patent License
AGENCY: National Institute of Standards and Technology, Commerce.
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institute of Standards and
Technology (``NIST''), U.S. Department of Commerce, is contemplating
the grant of an exclusive license in the United States of America, its
territories, possessions and commonwealths, to NIST's interest in the
invention embodied in U.S. Patent 5,389,523, titled, ``Liposome
Immunoanalysis By Flow Injection Assay'', filed July 23, 1992; NIST
Docket No. 92-054C to Kalibrant Limited, having a place of business at
2 Oakwood Drive, Loughborough Park, Loughboro, Leics LE11 3NH, United
Kingdom. The grant of the license would be for the following fields of
use (1) Human Clinical Diagnostics and Prognostics Including Central
Lab Testing and Blood Screening/Typing, specifically excluding Point-
of-Care Patient Monitoring, (2) Drug Discovery Including Combinatorial
Chemistry and High Throughput Screening Applications.
FOR FURTHER INFORMATION CONTACT:
J. Terry Lunch, National Institute of Standards and Technology, Office
of Technology Partnerships, 100 Bureau Drive, Stop 2200, Gaithersburg,
MD 20899-2200.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty-bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within sixty days from the date of this published
Notice, NIST receives written evidence and argument which establish
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR 404.7. The availability of the
invention for licensing was published in the Federal Register, Vol. 57,
No. 226 (November 23, 1992). NIST and Kalibrant Limited may enter into
a Cooperative Research and Development Agreement (CRADA) to further
development of the invention.
U.S. Patent application 07/917,426 is owned by the U.S. Government,
as represented by the Secretary of Commerce. The present invention
relates to a method of immunoanalysis that combines immobilized
immunochemistry with the technique of flow injection analysis, and
employs microscopic spherical structures called liposomes, or lipid
vesicles, as carriers of detectable reagents. Liposomes are modified on
their surface with analytical reagents, and carry in their internal
volume a very large number of fluorescent or electroactive molecules.
Aspects of this embodiment of the invention include chemistry for
covalent immobilization of antibody fragments in a specified
orientation, the use of liposomes in a flow injection analysis system,
and with reusable immunoreactants. Another aspect of the invention
involves the non-covalent binding of liposomes to a receptor for use in
a homogeneous assay. In another aspect of the invention the intensity
of scattered light is quantitated as a measure of liposome aggregation
in response to a concentration-dependent immunospecific reaction.
Dated: August 9, 1999.
Karen H. Brown,
Deputy Director.
[FR Doc. 99-21205 Filed 8-16-99; 8:45 am]
BILLING CODE 3510-13-M
